drug_type
RELEVANT_DRUG
intervention_type
monoclonal antibody (anti-HER2)
drug_description
Humanized IgG1 monoclonal antibody targeting HER2 (ERBB2); inhibits downstream signaling and mediates ADCC in HER2‑overexpressing tumors.
nci_thesaurus_concept_id
C1647
nci_thesaurus_preferred_term
Trastuzumab
nci_thesaurus_definition
A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)
drug_mesh_term
Trastuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 monoclonal antibody against HER2 (ERBB2) that binds the extracellular domain, inhibits receptor dimerization and downstream MAPK/PI3K signaling, and mediates antibody‑dependent cell‑mediated cytotoxicity (ADCC) against HER2‑overexpressing tumor cells.
drug_name
Trastuzumab
nct_id_drug_ref
NCT06121700